Long Non-coding RNA GAS5 Contributes to the Progression of Nonalcoholic Fatty Liver Disease by Targeting the MicroRNA-29a-3p/NOTCH2 Axis

Overview

Journal Bioengineered

Date 2022 Mar 24

PMID 35322757

Authors

Juanjuan Cui

Yang Wang

Haowei Xue

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) have been widely recognized as critical players in the development of nonalcoholic fatty liver disease (NAFLD), one of the most prevalent liver diseases globally. In this study, we established a HFD-induced NAFLD mouse model and explored the role of lncRNA GAS5 in NAFLD progression and its possible underlying mechanisms. We showed that NAFLD activity score was elevated in the HFD mice. GAS5 knockdown attenuated HFD-induced hepatic steatosis and lipid accumulation and reduced NAFLD activity score in HFD mice. In addition, GAS5 knockdown reduced serum triglyceride cholesterol levels and inhibited alanine aminotransferase and aspartate aminotransferase activities in HFD mice. Moreover, GAS5 overexpression enhanced NOTCH2 levels in liver cells and promoted NAFLD progression by sponging miR-29a-3p . Furthermore, miR-29a-3p inhibited NAFLD progression by targeting NOTCH2 . Overall, our results indicated that GAS5 acts as a sponge of miR-29a-3p to increase NOTCH2 expression and facilitate NAFLD progression by targeting the miR-29a-3p/NOTCH2 axis and demonstrated a new GAS5-mediated mechanism underlying NAFLD development, suggesting that GAS5 could be a potential therapeutic target of NAFLD. Alanine aminotransferase: ALT; Aspartate aminotransferase: AST; Enzyme linked immunosorbent assay: ELISA; Hepatocellular carcinoma: HCC; High-fat diet: HFD; Long non-coding RNA: Lnc RNA; Long non-coding RNA GAS5: GAS5; MicroRNAs: MiRNAs; Nonalcoholic fatty liver disease: NAFLD; Quantitative reverse transcription PCRs: RT-qPCRs; siRNA negative control: si-NC; Total cholesterol: TC; Triglyceride: TG.

Citing Articles

Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis.

Wade H, Pan K, Zhang B, Zheng W, Su Q eGastroenterology. 2025; 2(4):e100115.

PMID: 39872125 PMC: 11729351. DOI: 10.1136/egastro-2024-100115.

Exosome-mediated Transfer of lncRNA in Liver Associated Diseases; Uncovered Truths.

Saleh R, Hamad H, Najim M, Menon S, Kaur M, Sivaprasad G Cell Biochem Biophys. 2024; .

PMID: 39567423 DOI: 10.1007/s12013-024-01617-x.

Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?.

Soltanieh S, Khastar S, Kaur I, Kumar A, Bansal J, Fateh A Cell Biochem Biophys. 2024; 83(1):279-294.

PMID: 39377981 DOI: 10.1007/s12013-024-01555-8.

Screening of differentially expressed RNAs and identifying a ceRNA axis during cadmium-induced oxidative damage in pancreatic β cells.

Mou Y, Sun Y, Liu G, Zhang N, He Z, Gu S Sci Rep. 2024; 14(1):18962.

PMID: 39152192 PMC: 11329516. DOI: 10.1038/s41598-024-69937-9.

The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression.

Caputo V, Tarantino G, Santini S, Fracassi G, Balsano C Nutrients. 2023; 15(22).

PMID: 38004151 PMC: 10675587. DOI: 10.3390/nu15224757.

References

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Guo J, Zhou Y, Cheng Y, Fang W, Hu G, Wei J . Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice. Cell Physiol Biochem. 2018; 45(4):1487-1505. DOI: 10.1159/000487575. View

Kopp F, Mendell J . Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell. 2018; 172(3):393-407. PMC: 5978744. DOI: 10.1016/j.cell.2018.01.011. View

Long J, Dai W, Zheng Y, Zhao S . miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019; 25(1):26. PMC: 6567918. DOI: 10.1186/s10020-019-0085-2. View

Yang L, Roh Y, Song J, Zhang B, Liu C, Loomba R . Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2013; 59(2):483-95. PMC: 3946696. DOI: 10.1002/hep.26698. View

Zhu J, Zhang Z, Zhang Y, Li W, Zheng W, Yu J . MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7. Biochem Biophys Res Commun. 2018; 496(1):176-183. DOI: 10.1016/j.bbrc.2018.01.019. View

Santhekadur P, Kumar D, Sanyal A . Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2017; 68(2):230-237. PMC: 5775040. DOI: 10.1016/j.jhep.2017.10.031. View

Neuschwander-Tetri B . Non-alcoholic fatty liver disease. BMC Med. 2017; 15(1):45. PMC: 5330146. DOI: 10.1186/s12916-017-0806-8. View

10.

Fang Q, Shen Q, Li J, Yang Y, Guo J, Cheng Y . Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. Hepatol Res. 2019; 49(7):743-757. DOI: 10.1111/hepr.13330. View

11.

He H, Dai J, Feng J, He Q, Chen X, Dai W . FBXO31 modulates activation of hepatic stellate cells and liver fibrogenesis by promoting ubiquitination of Smad7. J Cell Biochem. 2019; 121(8-9):3711-3719. DOI: 10.1002/jcb.29528. View

12.

Bedossa P . Pathology of non-alcoholic fatty liver disease. Liver Int. 2017; 37 Suppl 1:85-89. DOI: 10.1111/liv.13301. View

13.

Ikejima K, Okumura K, Lang T, Honda H, Abe W, Yamashina S . The role of leptin in progression of non-alcoholic fatty liver disease. Hepatol Res. 2005; 33(2):151-4. DOI: 10.1016/j.hepres.2005.09.024. View

14.

Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T . MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett. 2016; 258:159-167. DOI: 10.1016/j.toxlet.2016.06.012. View

15.

Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal V . miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010; 207(8):1589-97. PMC: 2916139. DOI: 10.1084/jem.20100035. View

16.

Cobbina E, Akhlaghi F . Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211. PMC: 5576152. DOI: 10.1080/03602532.2017.1293683. View

17.

Sun Y, Song Y, Liu C, Geng J . LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. Biochem Biophys Res Commun. 2019; 516(2):584-590. DOI: 10.1016/j.bbrc.2019.06.104. View

18.

Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K . microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2014; 35(2):532-41. PMC: 4289469. DOI: 10.1111/liv.12633. View

19.

Shen X, Guo H, Xu J, Wang J . Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019; 234(10):18169-18179. DOI: 10.1002/jcp.28450. View

20.

Zhang B, Li H, Li D, Sun H, Li M, Hu H . Long noncoding RNA Mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p. Gene. 2019; 700:139-148. DOI: 10.1016/j.gene.2019.02.096. View